What is Raymond James’ Forecast for TSE:GUD Q4 Earnings?

Knight Therapeutics Inc. (TSE:GUD) – Stock analysts at Raymond James issued their Q4 2024 earnings estimates for Knight Therapeutics in a research note issued to investors on Wednesday, November 13th. Raymond James analyst R. Sarugaser expects that the company will earn $0.01 per share for the quarter. The consensus estimate for Knight Therapeutics’ current full-year earnings is $0.10 per share. Raymond James also issued estimates for Knight Therapeutics’ Q1 2025 earnings at $0.00 EPS and Q3 2025 earnings at $0.00 EPS.

Other analysts also recently issued reports about the stock. Stifel Nicolaus raised shares of Knight Therapeutics from a “hold” rating to a “buy” rating and lifted their price objective for the stock from C$5.75 to C$6.75 in a report on Tuesday, August 13th. Stifel Canada raised shares of Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, August 12th.

Knight Therapeutics Stock Up 1.4 %

Shares of TSE GUD opened at C$5.22 on Friday. The business has a 50-day moving average of C$5.72 and a 200-day moving average of C$5.74. The firm has a market capitalization of C$528.32 million, a price-to-earnings ratio of -26.10, a PEG ratio of -1,013.50 and a beta of 0.50. The company has a current ratio of 3.41, a quick ratio of 1.79 and a debt-to-equity ratio of 7.62. Knight Therapeutics has a 12 month low of C$5.07 and a 12 month high of C$6.23.

Insider Buying and Selling at Knight Therapeutics

In other news, insider Sime Armoyan sold 300,000 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of C$6.13, for a total transaction of C$1,839,000.00. Also, Director Samira Sakhia purchased 20,000 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The stock was acquired at an average price of C$5.15 per share, with a total value of C$103,000.00. Insiders own 45.62% of the company’s stock.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.